Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as PF-07264660 intravenous single ascending dose
PF-07264660 single ascending dose · 1 trial · 1 indication
To evaluate the safety and tolerability of PF 07264660, following single and multiple doses in healthy adults
To evaluate the safety and tolerability of PF 07264660, following single and multiple doses in healthy adults
Identify systolic and diastolic readings that are outside the normal range. The number and percentage of participants who experienced significant blood pressure change from baseline will be summarized
Identify pulse rate readings that are outside the normal range. The number and percentage of participants who experienced significant pulse rate change from baseline will be summarized
Identify temperature readings that are outside the normal range. The number and percentage of participants who experienced significant temperature change from baseline will be summarized
Identify laboratory abnormalities from baseline will be summarized
Determine the effect of the drug on heart rate The number and percentage of participants who experienced heart rate changes will be summarized
Determine the effect of the drug on QT interval. The number and percentage of participants who experienced QT interval changes will be summarized
Determine the effect of the drug on corrected QT interval. The number and percentage of participants who experienced corrected QT interval changes will be summarized
Determine the effect of the drug on PR interval. The number and percentage of participants who experienced PR interval changes will be summarized
Determine the effect of the drug on QRS interval. The number and percentage of participants who experienced QRS interval changes will be summarized
| Arm | Type | Description |
|---|---|---|
| PF-07264660 intravenous single ascending dose | EXPERIMENTAL | PF-07264660 will be administered intravenously |
| PF-07264660 subcutaneous multiple ascending dose | EXPERIMENTAL | PF-07264660 will be administered subcutaneously |
| Intravenous placebo | PLACEBO_COMPARATOR | Placebo will be administered intravenously |
| Subcutaneous Placebo | PLACEBO_COMPARATOR | Placebo will be administered subcutaneously |
| Name | Type | Description |
|---|---|---|
| PF-07264660 intravenous single ascending dose | DRUG | PF-07264660 will be administered intravenously in single ascending doses |
| PF-07264660 subcutaneous multiple ascending dose | DRUG | PF-07264660 will be administered subcutaneously in multiple ascending doses |
| Intravenous placebo | OTHER | Placebo will be administered intravenously in single ascending doses |
| subcutaneous placebo | OTHER | Placebo will be administered subcutaneously in multiple ascending doses |
Inclusion Criteria: * Healthy volunteer male and female participants between 18 to 65 years of age * Body Mass Index (BMI) of 17.5 to 32 kg/m2; and a total body weight \>50 kg (110 lb) Exclusion Criteria: * Evidence or history of clinically significant hematological, renal, endocrine, pulmonary, ...
PF-07264660 is an investigational small molecule developed by Pfizer, Inc. It has been studied in a Phase 1 single ascending dose trial in healthy adult participants. The specific disease or condition it is intended to treat has not been disclosed, and it remains in early clinical development.
PF-07264660 is being developed by Pfizer, Inc., which trades on the New York Stock Exchange under the ticker PFE. Pfizer sponsored the Phase 1 study of the compound conducted in the United States.
PF-07264660 is in Phase 1 clinical development. It is investigational and has not been approved by the FDA. One Phase 1 trial has been completed, and no active trials of PF-07264660 are currently listed.
PF-07264660 has been evaluated in one completed Phase 1 trial, NCT05496738, titled A Preliminary Study to Evaluate PF-07264660 in Healthy Participants. The trial enrolled 59 healthy adult volunteers in the United States and used a randomized, double-blind, placebo-controlled design.
Yes. PF-07264660 intravenous single ascending dose is another name for PF-07264660. The Phase 1 trial NCT05496738 studied single ascending intravenous doses of the compound in healthy participants, which is why the intravenous single ascending dose description is used alongside the base compound name.